Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. This event brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies.
The company will highlight its recent regulatory achievements, including FDA approval for a 505(2)(b) abbreviated pathway for human health applications, a sponsor fee waiver, and an Investigational New Animal Drug number (INAD) for animal health applications from the FDA Center for Veterinary Medicine.
Iris Bincovich, CEO of Innocan Pharma, will present at 2PM ET in the Lotus Suite West. The management team will also conduct one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule meetings online.
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) ha annunciato la sua partecipazione a The ThinkEquity Conference il 30 ottobre 2024, presso il Mandarin Oriental Hotel di New York. Questo evento riunisce investitori istituzionali, clienti aziendali e professionisti del settore per presentare innovazioni e strategie finanziarie.
La società evidenzierà i suoi recenti traguardi normativi, compresa l'approvazione della FDA per un percorso abbreviato 505(2)(b) per applicazioni relative alla salute umana, una esenzione dalla tassa per gli sponsor e un numero di Farmaco Nuovo per Uso Veterinario (INAD) per applicazioni legate alla salute animale dal Centro per la Medicina Veterinaria della FDA.
Iris Bincovich, CEO di Innocan Pharma, presenterà alle 14:00 ET nella Lotus Suite West. Il team di gestione condurrà anche incontri individuali con gli investitori durante tutta la giornata. Gli investitori interessati possono registrarsi per partecipare e pianificare incontri online.
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) ha anunciado su participación en The ThinkEquity Conference el 30 de octubre de 2024, en el Mandarin Oriental Hotel de Nueva York. Este evento reúne a inversores institucionales, clientes corporativos y profesionales de la industria para mostrar innovaciones y estrategias financieras.
La compañía destacará sus recientes logros regulatorios, incluida la aprobación de la FDA para un camino abreviado 505(2)(b) para aplicaciones de salud humana, una exención de tarifa para patrocinadores y un número de Medicamento Nuevo de Investigación Animal (INAD) para aplicaciones de salud animal del Centro de Medicina Veterinaria de la FDA.
Iris Bincovich, CEO de Innocan Pharma, presentará a las 2 PM ET en la Lotus Suite West. El equipo de gestión también llevará a cabo reuniones individuales con los inversores a lo largo del día. Los inversores interesados pueden registrarse para asistir y programar reuniones en línea.
이노칸 제약 (CSE: INNO, FSE: IP4, OTCQB: INNPF)는 The ThinkEquity Conference에 2024년 10월 30일 뉴욕의 만다린 오리엔탈 호텔에서 참여한다고 발표했습니다. 이 이벤트는 기관 투자자, 기업 고객 및 산업 전문가를 모아 혁신과 재무 전략을 선보입니다.
회사는 건강 관련 규제 성과를 강조할 예정이며, 이에는 인간 건강 응용을 위한 505(2)(b) 약식 경로에 대한 FDA 승인, 스폰서 수수료 면제 및 동물 건강 응용을 위한 조사 연구 신약 번호 (INAD)가 포함됩니다.
아이리스 빈코비치 이노칸 제약 CEO는 동부 표준시 오후 2시에 로터스 스위트 웨스트에서 발표할 예정입니다. 경영진 팀은 하루 종일 투자자와의 일대일 미팅도 진행합니다. 관심 있는 투자자는 온라인으로 참석 등록 및 미팅 일정을 예약할 수 있습니다.
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) a annoncé sa participation à The ThinkEquity Conference le 30 octobre 2024, à l'Hôtel Mandarin Oriental à New York. Cet événement réunit des investisseurs institutionnels, des clients d'entreprise et des professionnels de l'industrie pour présenter des innovations et des stratégies financières.
La société mettra en avant ses récents succès réglementaires, y compris l'approbation de la FDA pour une voie abrégée 505(2)(b) pour des applications liées à la santé humaine, une exonération des frais pour les sponsors, et un numéro d'Investigational New Animal Drug (INAD) pour les applications liées à la santé animale du Centre de Médecine Vétérinaire de la FDA.
Iris Bincovich, PDG d'Innocan Pharma, fera une présentation à 14h00 ET dans la Lotus Suite West. L'équipe de direction organisera également des réunions individuelles avec les investisseurs tout au long de la journée. Les investisseurs intéressés peuvent s'inscrire pour assister à l'événement et planifier des réunions en ligne.
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) hat seine Teilnahme an The ThinkEquity Conference am 30. Oktober 2024 im Mandarin Oriental Hotel in New York angekündigt. Diese Veranstaltung bringt institutionelle Investoren, Unternehmensklienten und Branchenexperten zusammen, um Innovationen und Finanzstrategien vorzustellen.
Das Unternehmen wird seine jüngsten regulatorischen Erfolge hervorheben, einschließlich FDA-Zulassung für einen abgekürzten Weg 505(2)(b) für Anwendungen zur menschlichen Gesundheit, eine Gebührenerlass für Sponsoren und eine Nummer für ein Neuer Forschungs- Tierarzneimittel (INAD) für Anwendungen zur Tiergesundheit vom FDA-Zentrum für Veterinärmedizin.
Iris Bincovich, CEO von Innocan Pharma, wird um 14:00 Uhr ET im Lotus Suite West präsentieren. Das Management-Team wird außerdem den ganzen Tag über persönliche Investorenmeetings abhalten. Interessierte Investoren können sich online registrieren, um an der Veranstaltung teilzunehmen und Meetings zu planen.
- None.
- None.
HERZLIYA, Israel and CALGARY, Alberta, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.
In addition, the Company will be discussing its recently achieved significant regulatory milestones, in particular, securing a U.S. Food and Drug Administration (FDA) approval for a 505(2)(b) abbreviated pathway for its human health applications. This included a sponsor fee waiver and an Investigational New Animal Drug number (INAD) for its animal health applications from the FDA Center for Veterinary Medicine.
Iris Bincovich, CEO of Innocan Pharma, will be presenting at 2PM ET at the Lotus Suite West on October 30th. Members of the Innocan Pharma management will also be holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetings here.
About ThinkEquity
ThinkEquity is a boutique investment bank founded by professionals who have collaborated for over a decade, collectively financing over
About Innocan Pharma:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.
For more information: www.innocanpharma.com
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
FAQ
When and where is Innocan Pharma (INNPF) presenting at the ThinkEquity Conference?
What recent regulatory milestones has Innocan Pharma (INNPF) achieved?
Who will be presenting for Innocan Pharma (INNPF) at the ThinkEquity Conference?
What is the focus of Innocan Pharma's (INNPF) business?
How can investors participate in meetings with Innocan Pharma (INNPF) at the ThinkEquity Conference?
